PKPD and cardiac single cell modeling of a DDI study with a CYP3A4 substrate and itraconazole to quantify the effects on QT interval duration

[1]  B. Hosmane,et al.  Use of Early Clinical Trial Data to Support Thorough QT Study Waiver for Upadacitinib and Utility of Food Effect to Demonstrate ECG Assay Sensitivity , 2017, Clinical pharmacology and therapeutics.

[2]  G. Ferber,et al.  Estimation of the Power of the Food Effect on QTc to Show Assay Sensitivity , 2017, Journal of clinical pharmacology.

[3]  P. Chalus,et al.  Characterising Drug Release from Immediate-Release Formulations of a Poorly Soluble Compound, Basmisanil, Through Absorption Modelling and Dissolution Testing , 2017, The AAPS Journal.

[4]  P. Chalus,et al.  Characterising Drug Release from Immediate-Release Formulations of a Poorly Soluble Compound, Basmisanil, Through Absorption Modelling and Dissolution Testing , 2017, The AAPS Journal.

[5]  Borje Darpo,et al.  Concentration–Response Modeling of ECG Data From Early‐Phase Clinical Studies as an Alternative Clinical and Regulatory Approach to Assessing QT Risk — Experience From the Development Program of Lemborexant , 2017, Journal of clinical pharmacology.

[6]  T. Colatsky,et al.  The Comprehensive in Vitro Proarrhythmia Assay (CiPA) initiative - Update on progress. , 2016, Journal of pharmacological and toxicological methods.

[7]  S. Van Huffel,et al.  Influence of food intake on the QT and QT/RR relation. , 2016, Journal of electrocardiology.

[8]  C. Garnett,et al.  A Quantitative Framework to Evaluate Proarrhythmic Risk in a First‐in‐Human Study to Support Waiver of a Thorough QT Study , 2015, Clinical pharmacology and therapeutics.

[9]  N. Stockbridge,et al.  Implications of the IQ-CSRC Prospective Study: Time to Revise ICH E14 , 2015, Drug Safety.

[10]  R. Upton,et al.  Population Pharmacokinetic Modeling of Itraconazole and Hydroxyitraconazole for Oral SUBA-Itraconazole and Sporanox Capsule Formulations in Healthy Subjects in Fed and Fasted States , 2015, Antimicrobial Agents and Chemotherapy.

[11]  C Garnett,et al.  Results From the IQ‐CSRC Prospective Study Support Replacement of the Thorough QT Study by QT Assessment in the Early Clinical Phase , 2015, Clinical pharmacology and therapeutics.

[12]  B. Houk,et al.  Effect of axitinib on the QT interval in healthy volunteers , 2015, Cancer Chemotherapy and Pharmacology.

[13]  S. Hall,et al.  Itraconazole and Clarithromycin as Ketoconazole Alternatives for Clinical CYP3A Inhibition Studies , 2014, Clinical pharmacology and therapeutics.

[14]  P. Stang,et al.  Validation of a population‐based method to assess drug‐induced alterations in the QT interval: a self‐controlled crossover study , 2013, Pharmacoepidemiology and drug safety.

[15]  Yusheng Qu,et al.  Itraconazole decreases left ventricular contractility in isolated rabbit heart: mechanism of action. , 2013, Toxicology and applied pharmacology.

[16]  A. Camm,et al.  Shortening of the QT Interval After Food Can Be Used to Demonstrate Assay Sensitivity in Thorough QT Studies , 2012, Journal of clinical pharmacology.

[17]  Ho-Chul Shin,et al.  Blockade of K+ and Ca2+ channels by azole antifungal agents in neonatal rat ventricular myocytes. , 2012, Biological & pharmaceutical bulletin.

[18]  B. Tyl,et al.  Lack of Significant Effect of Bilastine Administered at Therapeutic and Supratherapeutic Doses and Concomitantly With Ketoconazole on Ventricular Repolarization: Results of a Thorough QT Study (TQTS) With QT‐Concentration Analysis , 2012, Journal of clinical pharmacology.

[19]  Gary R. Mirams,et al.  Simulation of multiple ion channel block provides improved early prediction of compounds’ clinical torsadogenic risk , 2011, Cardiovascular research.

[20]  J. Xue.  Robust QT Interval Estimation—From Algorithm to Validation , 2009, Annals of noninvasive electrocardiology : the official journal of the International Society for Holter and Noninvasive Electrocardiology, Inc.

[21]  K. T. ten Tusscher,et al.  Alternans and spiral breakup in a human ventricular tissue model. , 2006, American journal of physiology. Heart and circulatory physiology.

[22]  J. Shim,et al.  Combined Effects of Itraconazole and CYP2D6*10 Genetic Polymorphism on the Pharmacokinetics and Pharmacodynamics of Haloperidol in Healthy Subjects , 2006, Journal of clinical psychopharmacology.

[23]  V. Piotrovsky,et al.  Pharmacokinetic-pharmacodynamic modeling in the data analysis and interpretation of drug-induced QT/QTc prolongation , 2005, The AAPS Journal.

[24]  B. Fermini,et al.  The impact of drug-induced QT interval prolongation on drug discovery and development , 2003, Nature Reviews Drug Discovery.

[25]  S. Harendza,et al.  How can we improve teaching of ECG interpretation skills? Findings from a prospective randomised trial. , 2016, Journal of electrocardiology.

[26]  Hans Guenter Schaefer,et al.  Semi-Mechanistic Population Pharmacokinetic Drug-Drug Interaction Modelling of a Long Half-Life Substrate and Itraconazole , 2010, Clinical pharmacokinetics.